Dragon Boat Pharmaceutical

Announces First Patient Dosed

in the Phase I Clinical Trial of BC006 in China

Focus on the development and

production of antibody drugs

Innovation for a healthier world

Scroll down
Company Overview
Devoting to novel biologics development

Dragon Boat Pharmaceutical founded in 2005, is a biotech company committed to the discovery and development of biologics drugs with a priority focuing on gastrointestinal (GI) cancers. We are dedicated to bringing novel drugs to global patients with GI cancers and autoimmune diseases. In 2013, Dragon boat biopharmaceutical was acquired as a subsidiary company of Guilin Sanjin (SHE:002275). With insistent investment to R&D and excellent drug discovery capability, Dragon boat Pharmaceutical became a leading innovative biotech company in China.

  • 5000 +
    square meters R&D Center
  • 70 %+
    expenses to R&D
  • 160 +
    employees in the R&D team
  • 9
    drug candidates in pipeline
Systemic Development Platform
In-house systemic platform covers discovery,
development, and manufacturing

We care about the unmet medical needs of patients. Through layout strategy in intellectual property, and in-house systematic R&D platform, we build up a streamline that covers from the early discovery to manufacturing, including analytical testing, process development, GMP manufacturing, quality management, and regulatory affairs.

  • Analysis and Evaluation Platform

    Analysis and Evaluation Platform

    The platform is equipped with state-of-the-art instruments, such as high-resolution mass spectrometers, flow cytometer, Fortebio, capillary electrophoresis, ultra-high performance liquid chromatograph, iCE3, qPCR instrument, plate reader, etc. It also has a variety of reporter gene cell lines that facilitate the functional assay evaluation, such as ADCC, ADCP, etc. The platform has comprehensive analytical technologies to support IND/BLA filing, including drug developability assessment, antibody Fc engineering, analytical method development and validation, releasing and stability testing, clinical stability studies, structure characterization, potency and epitope studies, degradation pathway studies, CQA establishment, and quality comparability study.

    Analysis and Evaluation Platform
  • Process Development Platform

    Process Development Platform

    The platform is furnished with a variety of advanced instruments, including Cytena c.sight, Sartorius 24×Ambr15, Thermo G3Lab 16×3L BRs, and AKTA Pure M& Avant protein chromatography system, etc., which can meet the process development needs from cell line construction, upstream cell culture, protein purification to formulation filling. Meanwhile, the platform has a highly efficient CHO-K1 expression system, which has been validated in multiple mAbs, bi-specific and Sd-Fc antibodies. With the highest 9.2 g/L, most production cell line expression levels reach 4-7 g/L and the IND filing can be achieved within 15 months.

    Process Development Platform
  • GMP Manufacturing Platform

    GMP Manufacturing Platform

    The platform is equipped with Cytiva, Sartiorus and other advanced bioreactors of famous brand, protein chromatography system and filling system, etc., for mammal cell culture, protein purification to formulation filling; Manufacturing facilities meet the requirements of Good Manufacturing Practice (GMP) , FDA, NMPA and EMA. The pilot capacity is 3 × 200L and 1 × 500L disposable bioreactors, which can flexibly provide qualified samples from preclinical stage to Phase I and Phase II clinical.

    GMP Manufacturing Platform
  • Quality Management Platform

    Quality Management Platform

    The platform adheres to our quality policy of "innovation, ingenuity, quality-oriented and sincerity”, and follows regulations of health authorities in different countries (CN, EU, and US), covering through the total four stages of the product life cycle: drug development, technology transfer, manufacturing, withdrawn(termination). We adhere to the concept of quality from design, and integrate quality management into products, processes and analytical testing methods, to make sure products meet the quality standards and ensure safety and efficacy.

    Quality Management Platform
  • Regulatory Affairs Platform

    Regulatory Affairs Platform

    The platform provides regulatory support from the start to the end, including regulatory affairs strategy, application submission, communication with health authorities and preparing filling materials. Our regulatory team has a deep understanding of guidelines of NMPA, FDA, and EMA, and keep tracking updated guidelines. Our strict summarizing ability of scientific data and rigorous review ability can solve the issues of regulatory affairs efficiently.

    Regulatory Affairs Platform
XML 地图